Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study

被引:515
作者
Lee, J
Suh, C
Park, YH
Ko, YH
Bang, SM
Lee, JH
Lee, DH
Huh, J
Oh, SY
Kwon, HC
Kim, HJ
Lee, SI
Kim, JH
Park, J
Oh, SJ
Kim, K
Jung, C
Park, K
Kim, WS
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol,Kangnam Ku, Seoul 135710, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul 135710, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Diagnost Pathol,Div Hematol Oncol, Ulsan, South Korea
[4] Dankook Univ, Sch Med, Dept Hematol Oncol, Seoul, South Korea
[5] Hallym Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[6] Natl Canc Ctr, Res Inst Hosp, Goyang 411769, Gyeonggi, South Korea
[7] Gachun Med Sch, Gil Med Ctr, Dept Hematol Oncol, Inchon, South Korea
[8] Dong A Univ, Coll Med, Dong A Canc Ctr, Pusan, South Korea
[9] Sungkyunkwan Univ, Sch Med, Dept Internal Med, Seoul, South Korea
[10] Jeju Natl Univ, Coll Med, Cheju, South Korea
关键词
D O I
10.1200/JCO.2005.04.1384
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Patients with natural killer T (NK/T) -cell lymphomas have poor survival outcome, and for this condition there is no optimal therapy. The purpose of this study was to design a prognostic model specifically for extrancidal NK/T-cell lymphoma, which can identify high-risk patients who need more aggressive therapy. Patients and Methods This multicenter retrospective study was comprised of 262 patients who were diagnosed with NK/T-cell lymphoma. Results After a median follow-up duration of 51.2 months, 5-year overall survival rate in 262 patients was 49.5%. Prognostic factors for survival were "B" symptoms (P = .0003; relative risk, 2.202; 95% Cl, 1.446 to 3.353), stage (P = .0006; relative risk, 2.366; 95% Cl, 1.462 to 3.828), lactate dehydrogenase (LDH) level (P = .0005; relative risk, 2.278; 95% Cl, 1.442 to 3.598), and regional lymph nodes (P = .0044; relative risk, 1.546; 95% Cl, 1.009 to 2.367). Of 262 patients, 219 had complete information on four parameters. We identified four different risk groups: group 1, no adverse factor; group 2, one factor;, group 3, two factors; and group 4, three or four factors. The new model showed a superior prognostic discrimination as compared with the International Prognostic Index (IPI). Notably, the distribution of patients was balanced when a new model was :adopted (group 1, 27%; group 2, 31%; group 3, 20%; group 4, 22%), whereas 81% of patients were categorized as low or low-intermediate risks using IPI. Conclusion The newly proposed model for extranodal NK/T-cell lymphoma demonstrated a more balanced distribution of patients into four groups with better prognostic discrimination as compared with the IPI.
引用
收藏
页码:612 / 618
页数:7
相关论文
共 37 条
[31]  
Logsdon MD, 1997, CANCER, V80, P477, DOI 10.1002/(SICI)1097-0142(19970801)80:3<477::AID-CNCR16>3.0.CO
[32]  
2-U
[33]  
ROBBINS KT, 1985, CANCER, V56, P814, DOI 10.1002/1097-0142(19850815)56:4<814::AID-CNCR2820560419>3.0.CO
[34]  
2-P
[35]  
Siu LLP, 2002, HISTOL HISTOPATHOL, V17, P539, DOI 10.14670/HH-17.539
[36]   Follicular lymphoma international prognostic index [J].
Solal-Céligny, P ;
Roy, P ;
Colombat, P ;
White, J ;
Armitage, JO ;
Arranz-Saez, R ;
Au, WY ;
Bellei, M ;
Brice, P ;
Caballero, D ;
Coiffier, B ;
Conde-Garcia, E ;
Doyen, C ;
Federico, M ;
Fisher, RI ;
Garcia-Conde, JF ;
Guglielmi, C ;
Hageenbeek, A ;
Haïoun, C ;
LeBlanc, M ;
Lister, AT ;
Lopez-Guillermo, A ;
McLaughlin, P ;
Milpied, N ;
Morel, P ;
Mounier, N ;
Proctor, SJ ;
Rohatiner, A ;
Smith, P ;
Soubeyran, P ;
Tilly, H ;
Vitolo, U ;
Zinzani, PL ;
Zucca, E ;
Montserrat, E .
BLOOD, 2004, 104 (05) :1258-1265
[37]   Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan [J].
You, JY ;
Chi, KH ;
Yang, MH ;
Chen, CC ;
Ho, CH ;
Chau, WK ;
Hsu, HC ;
Gau, JP ;
Tzeng, CH ;
Liu, JH ;
Chen, PM ;
Chiou, TJ .
ANNALS OF ONCOLOGY, 2004, 15 (04) :618-625